Medifast Beheer

Beheer criteriumcontroles 3/4

De CEO Medifast is Dan Chard, benoemd in Oct2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.04M, bestaande uit 14.2% salaris en 85.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.46% van de aandelen van het bedrijf, ter waarde MX$ 59.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 7.9 jaar.

Belangrijke informatie

Dan Chard

Algemeen directeur

US$7.0m

Totale compensatie

Percentage CEO-salaris	14.2%
Dienstverband CEO	7.9yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	4.5yrs
Gemiddelde ambtstermijn bestuur	7.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dan Chard's beloning veranderd ten opzichte van Medifast's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$29m
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m
Sep 30 2018	n/a	n/a	US$47m
Jun 30 2018	n/a	n/a	US$40m
Mar 31 2018	n/a	n/a	US$34m
Dec 31 2017	US$2m	US$650k	US$28m

Compensatie versus markt: De totale vergoeding ($USD 7.04M ) Dan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 346.94K ).

Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dan Chard (59 yo)

7.9yrs

Tenure

US$7,039,062

Compensatie

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Chard	Executive Chairman & CEO	7.9yrs	US$7.04m	1.46% MX$ 59.1m
James Maloney	Chief Financial Officer	4.2yrs	US$2.01m	0.092% MX$ 3.7m
Anthony Tyree	Chief Business Operations Officer	2.7yrs	US$1.61m	0.12% MX$ 4.7m
Jason Groves	Executive VP	12.8yrs	US$1.63m	0.12% MX$ 4.7m
Nicholas Johnson	Chief Field Operations Officer	5.6yrs	US$1.70m	0.095% MX$ 3.9m
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	3yrs	geen gegevens	0.0052% MX$ 210.5k
Steven Zenker	Vice President of Investor Relations	1.5yrs	geen gegevens	geen gegevens
Claudia Greninger	Chief Human Resources Officer	4.9yrs	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MED * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Chard	Executive Chairman & CEO	7.9yrs	US$7.04m	1.46% MX$ 59.1m
Jeffrey Brown	Lead Independent Director	9.3yrs	US$263.42k	0.15% MX$ 5.9m
George Bray	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Hoer	Independent Director	6.3yrs	US$249.72k	0.079% MX$ 3.2m
Andrea Thomas	Independent Director	5.3yrs	US$249.72k	0.059% MX$ 2.4m
John Foreyt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ming Xian	Independent Director	6.3yrs	US$219.61k	geen gegevens
Lawrence Cheskin	Chairman of Scientific Advisory Board	15.8yrs	geen gegevens	geen gegevens
Sylvia Rowe	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scott Schlackman	Independent Director	9.3yrs	US$252.44k	0.073% MX$ 3.0m
John Hayes	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Messina	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.9yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MED * wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).

Medifast Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient new directors

Insufficient new directors

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Insufficient new directors

Insufficient new directors

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought Mex$190k worth of stock

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.30 in 3Q 2022)

Insufficient new directors

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insufficient new directors

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Insufficient new directors

Insufficient new directors

Medifast Unveils New Product Line, Optavia Active

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Medifast, Inc. Revises Earnings Guidance for the Year 2022

Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Insufficient new directors

Upcoming dividend of US$1.64 per share

Medifast Announces Quarterly Dividend, Payable on November 8, 2022

Insufficient new directors

Lead Independent Director recently bought Mex$10m worth of stock

Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021)

Insufficient new directors

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast Announces New Scientific Advisory Board Appointments

Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Insufficient new directors

Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index

Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022

Insufficient new directors

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast, Inc., Annual General Meeting, Jun 15, 2022

Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

Medifast, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Investor sentiment deteriorated over the past week

Independent Director recently sold Mex$3.1m worth of stock

Investor sentiment deteriorated over the past week

Medifast, Inc. Provides Earnings Guidance for 2021

Independent Director recently sold Mex$6.1m worth of stock

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$3.49 (vs US$1.57 in 1Q 2020)

Medifast, Inc. Announces Earnings Guidance for the Full Year 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie